Lung scarring, known medically as pulmonary fibrosis, is a condition in which normal, flexible lung tissue is gradually replaced by thick, stiff scar tissue that makes it progressively harder to breathe. The scarring disrupts the tiny air sacs where oxygen enters the bloodstream, and once it reaches a certain point, the damage is permanent. Dozens of different triggers can set the process in motion, from inhaled toxins to autoimmune diseases to infections, though in many cases no cause is ever identified.
How Scarring Develops in the Lungs
Healthy lung tissue is remarkably thin and elastic. The walls of the air sacs are just one or two cells thick, which allows oxygen and carbon dioxide to pass through easily. When those delicate walls are injured, the body launches a repair process that involves inflammation and the laying down of new structural proteins, much like a wound healing on the skin. In most organs, this repair resolves and the tissue returns close to normal. In the lungs, however, the repair process can go haywire: specialized cells called fibroblasts become overactive, producing excessive amounts of structural material that accumulates in and around the air sacs.
This buildup stiffens the lung and thickens the barrier between air and blood, making gas exchange increasingly difficult. A review of the underlying biology describes pulmonary fibrosis as involving “extensive alterations of cellular fate and function and excessive accumulation of extracellular matrix, leading to lung tissue scarring and impaired respiratory function.”1Europe PMC. Pulmonary fibrosis: pathogenesis and therapeutic strategies One critical point is that if the underlying architecture of the lung is still intact, therapeutic intervention can potentially halt or partially reverse the remodeling. But once that architecture is destroyed, permanent fibrosis and loss of function are inevitable.2PubMed Central. Inflammation-associated remodelling and fibrosis in the lung – a process and an end point That distinction between “still remodeling” and “structurally gone” is at the heart of why early detection matters so much.
Known Causes of Lung Scarring
The list of things that can trigger pulmonary fibrosis is long, and grouping them helps make sense of the landscape.
Occupational and Environmental Exposures
Asbestos is probably the most widely known culprit. Inhaling asbestos fibers over time causes asbestosis, a form of pulmonary fibrosis directly tied to how much asbestos a person breathed and for how long.3Europe PMC / Elsevier. Asbestos-induced lung diseases: an update. Other mineral dusts carry similar risks: silica dust (from mining, stone cutting, and sandblasting), coal dust, and grain dust have all been linked to lung scarring. These occupational lung diseases tend to develop slowly, often showing up years or decades after the exposure began. Some inhaled organic materials, like bird droppings or mold spores, can also trigger a condition called hypersensitivity pneumonitis, which can progress to fibrosis if the exposure continues.
Autoimmune Diseases
Several autoimmune conditions attack the lungs alongside their primary targets. Rheumatoid arthritis is one of the more common examples. Interstitial lung disease is actually a leading cause of death in rheumatoid arthritis patients, driven partly by the same inflammatory signaling molecules that damage the joints.4Journal of Inflammation Research (Dove Press / PubMed Central). Role of Interleukin-6 in Rheumatoid Arthritis-Associated Interstitial Lung Disease: Focus on the JAK/STAT Pathway and Macrophage Polarization Scleroderma, lupus, and inflammatory myopathies can also produce lung scarring. Because the lung involvement can be silent at first, people with these conditions often need periodic lung-function monitoring even when they feel fine.
Infections
Severe lung infections can leave scars behind once the infection clears. Tuberculosis has been doing this for centuries. More recently, COVID-19 pushed this issue into the spotlight. The virus primarily injures the lungs, and in severe cases it triggers acute respiratory distress syndrome. Pulmonary fibrosis is a well-recognized consequence of that kind of severe lung injury, and researchers have been tracking whether COVID-19 survivors will face lasting fibrotic lung damage.5PubMed Central. From ARDS to pulmonary fibrosis: the next phase of the COVID-19 pandemic? Not every pneumonia patient develops lasting scarring, but the risk rises sharply with the severity of the initial illness.
Medications and Radiation
Certain drugs are known to cause lung fibrosis as a side effect. Chemotherapy agents like bleomycin and methotrexate are classic offenders. The heart medication amiodarone and some antibiotics (particularly nitrofurantoin with long-term use) have also been implicated. Radiation therapy directed at the chest, commonly used for breast or lung cancer, can produce radiation fibrosis in the treated area. Drug-induced fibrosis is worth knowing about because stopping the responsible medication early sometimes halts progression.
When No Cause Is Found
In a large share of cases, no trigger can be identified. This is called idiopathic pulmonary fibrosis, or IPF, and it is the most common and most aggressive form of the disease. IPF typically appears in people over 50 and is more common in men and in current or former smokers. Research into its genetic underpinnings has turned up mutations in genes involved in maintaining telomeres, the protective caps on the ends of chromosomes. Mutations in the TERT gene are the most frequently identified, though they appear mainly in families with multiple affected members rather than in isolated cases.6European Respiratory Journal. The genetic basis of idiopathic pulmonary fibrosis A separate set of rare genetic variants affects surfactant biology, accounting for roughly one to three percent of IPF cases, and these patients tend to be younger.7Europe PMC. Rare surfactant-related variants in familial and sporadic pulmonary fibrosis.
Symptoms and How They Progress
Lung scarring tends to develop slowly enough that people often dismiss early symptoms as being out of shape or getting older. The hallmark symptom is breathlessness that worsens over months or years, initially noticeable only during exercise and eventually present at rest. A persistent dry cough that does not respond to typical cough treatments is another common early sign. Fatigue and a general sense of low energy round out the core symptoms, and these can be just as debilitating as the breathing difficulty itself.8PubMed. Patient and caregiver shared experiences of pulmonary fibrosis (PF): A systematic literature review
As the disease advances, other signs appear. Clubbing of the fingertips, where the nails curve downward and the fingertips widen, is seen in a substantial number of patients and reflects chronic low oxygen levels. Weight loss, aching muscles and joints, and swelling in the legs from the strain on the heart can develop in later stages. A doctor listening to the lungs with a stethoscope may hear a distinctive sound often compared to the tearing of Velcro, which reflects the stiff, scarred lung tissue snapping open during breathing.
Getting a Diagnosis
Lung scarring is often suspected based on symptoms and a physical exam, but confirming it and identifying the specific type requires a few steps.
Imaging
A standard chest X-ray can show widespread haziness or a reticular pattern in the lungs, but high-resolution CT scanning is the real workhorse. On a CT scan, pulmonary fibrosis shows characteristic patterns: ground-glass opacities (a hazy look suggesting early or active disease), reticular markings (a net-like pattern of thickened tissue), traction bronchiectasis (airways pulled open by surrounding scar tissue), and honeycombing (clusters of small cystic air spaces, typically less than 10 mm across, with well-defined walls, concentrated near the outer edges of the lungs).9European Respiratory Review. Imaging: how to recognise idiopathic pulmonary fibrosis Honeycombing is the most specific sign of established fibrosis and, when present in the right pattern, can sometimes clinch a diagnosis of IPF without a lung biopsy. Distinguishing honeycombing from emphysema or dilated airways can be tricky even for experienced radiologists, though, and scrolling through thin-slice images or looking at reconstructed views helps sort it out.
Breathing Tests
Pulmonary function tests measure how well the lungs move air and transfer oxygen. In fibrotic lung disease, the lungs become stiff and small, so total lung capacity and the amount of air you can forcefully exhale both drop. A particularly sensitive test is the diffusing capacity for carbon monoxide, which measures how efficiently gas crosses from the air sacs into the blood. This value typically falls early in fibrosis because the scarred, thickened tissue slows gas transfer.10European Respiratory Journal. Idiopathic pulmonary fibrosis is associated with a preferential alteration of kCO rather than of DLCO Tracking these numbers over time is one of the primary ways doctors gauge whether the disease is stable or worsening.
Treatment Options
There is currently no treatment that reverses established lung scarring. The goals of therapy are to slow the progression, manage symptoms, and preserve quality of life for as long as possible.
Antifibrotic Drugs
Two medications, pirfenidone and nintedanib, are approved specifically for IPF and are increasingly used in other forms of progressive fibrotic lung disease. Both slow the rate at which lung function declines, but their effectiveness remains limited. Research describes them as drugs that “only slow clinical progression” rather than halting or reversing the disease.11PubMed Central. p53-miR-34a feedback in lung fibroblasts regulates antifibrotic effects of CSP7, nintedanib, and pirfenidone Both drugs come with side effects, particularly gastrointestinal issues like nausea and diarrhea (more common with nintedanib) and skin sensitivity to sunlight (more common with pirfenidone). Even with these drawbacks, they are a meaningful step forward from the era before antifibrotics, when there was essentially nothing to offer beyond supportive care. Some research has explored whether combining the two drugs might produce added benefit, and early evidence from laboratory studies suggests their antifibrotic effects may be additive.12PubMed. Pirfenidone and nintedanib exert additive antifibrotic effects by the SPP1-AKT pathway in macrophages and fibroblasts
Pulmonary Rehabilitation
Structured exercise programs supervised by respiratory therapists are one of the most effective ways to improve day-to-day function. Pulmonary rehabilitation does not change the underlying scarring, but it strengthens the muscles used for breathing, improves exercise tolerance, and reduces the sensation of breathlessness. In a real-world comparison, about 88% of IPF patients reported feeling “much better” or “a little better” after completing a pulmonary rehabilitation program, with improvements in walking distance and quality-of-life scores that were comparable to those seen in patients with other chronic lung diseases.13PubMed Central. Pulmonary Rehabilitation in Idiopathic Pulmonary Fibrosis and COPD A Propensity-Matched Real-World Study
Supplemental Oxygen
As the disease progresses and blood oxygen levels drop, supplemental oxygen becomes necessary. Initially this may only be needed during exercise or sleep, but eventually many patients use it around the clock. While oxygen does not slow the scarring process, maintaining adequate oxygen levels reduces strain on the heart, lessens breathlessness, and helps people remain more active.
Lung Transplantation
For younger, otherwise healthy patients with advanced disease, lung transplantation is the only option that can meaningfully extend life. One study found that transplantation reduced the risk of death by about 75% compared to staying on the waiting list.14The Journal of Thoracic and Cardiovascular Surgery. Survival benefit of lung transplantation for patients with idiopathic pulmonary fibrosis However, the window for transplant is narrow and the logistics are challenging. Patients with fibrotic lung disease face the highest mortality rate among all groups waiting for transplant organs, with one Japanese study reporting that about half of fibrosis patients on the waiting list died before receiving a transplant.15PubMed Central. Waiting time and mortality rate on lung transplant candidates in Japan: a single-center retrospective cohort study Because disease progression can be unpredictable and acute deterioration can happen suddenly, guidelines strongly encourage early referral to a transplant center so that patients are already evaluated and listed before they reach a crisis.16PubMed Central. Idiopathic Pulmonary Fibrosis and Lung Transplantation: When it is Feasible
Acute Exacerbations and Complications
One of the most feared aspects of pulmonary fibrosis is the acute exacerbation: a sudden, unexplained worsening of breathing over days to weeks, often requiring hospitalization and mechanical ventilation. These episodes carry high mortality rates and can rapidly accelerate the course of the disease. Research in patients with advanced IPF found that acute exacerbations were strongly associated with increased mortality, and that patients who already had elevated pressures in the blood vessels of the lungs (pulmonary hypertension) were at significantly greater risk of experiencing one.17PubMed. Acute exacerbations and pulmonary hypertension in advanced idiopathic pulmonary fibrosis Pulmonary hypertension itself develops in a subset of fibrosis patients as the scar tissue compresses and destroys the small blood vessels of the lungs, forcing the right side of the heart to work harder.
Lung cancer is another serious complication. People with pulmonary fibrosis have a higher risk of developing lung cancer than the general population, independent of smoking history. The chronic tissue damage and abnormal cell turnover in fibrotic lungs are thought to create a fertile environment for malignancy.
Prognosis and Predicting Outcomes
The course of lung scarring varies enormously depending on the type and cause. Some forms caused by medication or environmental exposures stabilize once the trigger is removed. Autoimmune-related fibrosis may respond to immunosuppressive therapy and follow a slower trajectory. IPF, however, carries the worst prognosis among the fibrotic lung diseases, with a median survival that is often cited at three to five years from diagnosis, though individual outcomes span a wide range.
Doctors use staging tools to estimate where a given patient falls on the spectrum. The GAP model, one of the most widely used, combines gender, age, and two lung-function measurements (forced vital capacity and diffusing capacity) to predict outcomes.18PubMed Central. Staging of idiopathic pulmonary fibrosis: past, present and future Newer approaches are incorporating CT-based analysis. One recent study used automated airway measurements from high-resolution CT scans to predict mortality and disease progression even after accounting for traditional severity measures, and combining these imaging markers with diffusing capacity produced strong predictive accuracy.19PubMed Central. Prognostication in patients with idiopathic pulmonary fibrosis using quantitative airway analysis from HRCT: a retrospective study These tools matter because they help clinicians make timely decisions about transplant referral, antifibrotic therapy, and advance care planning.
Emerging Treatments
The limitations of current antifibrotic drugs have driven intense research into new approaches. One promising direction borrows from cancer biology. In pulmonary fibrosis, activated fibroblasts invade the surrounding tissue in a way that parallels how cancer cells spread. Several drugs originally developed to block cancer-cell invasion are now being tested for their ability to do the same thing to fibroblasts in the lungs. Delivering these drugs by inhalation rather than as pills or injections is also being explored, with the idea that getting the medication directly to the lungs could improve its local effectiveness while reducing side effects elsewhere in the body.20PubMed. Pharmacological targeting of ECM homeostasis, fibroblast activation and invasion for the treatment of pulmonary fibrosis
Animal research has also shown that combination therapy with existing and experimental antifibrotic agents can improve lung function and survival beyond what any single drug achieves alone.11PubMed Central. p53-miR-34a feedback in lung fibroblasts regulates antifibrotic effects of CSP7, nintedanib, and pirfenidone These are still early-stage findings, but they suggest the field may eventually move from single drugs that modestly slow decline toward combination regimens that more effectively arrest or even partially reverse fibrosis.
The Role of Acid Reflux
One of the more surprising connections in pulmonary fibrosis research is the link between gastroesophageal reflux (acid reflux) and lung scarring, particularly in IPF. Reflux is remarkably common in IPF patients, and it is frequently silent, meaning people have it without the typical heartburn symptoms. The concern is that tiny amounts of stomach acid and digestive enzymes repeatedly reach the lower airways (a process called microaspiration), causing ongoing low-grade injury to already vulnerable lung tissue.21PubMed Central. The Role of Gastroesophageal Reflux and Microaspiration in Idiopathic Pulmonary Fibrosis
Some data suggest that treating reflux, either with acid-suppressing medications or with anti-reflux surgery, may slow the decline in lung function and improve survival in IPF. International treatment guidelines have recommended proton pump inhibitors for IPF patients partly on this basis, though the evidence remains debated.22PubMed Central. Idiopathic pulmonary fibrosis and GERD: links and risks Whether reflux treatment truly changes the disease course or simply addresses a common comorbidity is still being studied, but it is a low-risk intervention that many pulmonologists consider worthwhile.
Psychological Burden on Patients and Caregivers
Living with progressive lung scarring takes a toll that extends well beyond the lungs. Anxiety and depression are common in people with IPF. Research has found that these psychological symptoms are tied to the severity of breathlessness and fatigue rather than to lung-function numbers alone, meaning that two patients with similar test results can have very different emotional experiences depending on how symptomatic they feel.23PubMed Central. The Impact of Disease Severity and Symptoms on Anxiety and Depression in Individuals With Idiopathic Pulmonary Fibrosis The progressive nature of the disease adds its own kind of distress: knowing that the condition is unlikely to improve, and managing the uncertainty of not knowing how fast it will worsen, weighs heavily on both patients and their families.
Caregivers face their own set of challenges. As the disease advances, patients need increasing help with daily activities, oxygen equipment management, and transportation to medical appointments. Systematic reviews of patient and caregiver experiences consistently highlight breathlessness, fatigue, and cough as the symptoms that most disrupt daily life, while also emphasizing that psychological distress in this population is underrecognized and undertreated.8PubMed. Patient and caregiver shared experiences of pulmonary fibrosis (PF): A systematic literature review Getting appropriate mental health support, palliative care input, and peer support connected early in the disease course can meaningfully improve quality of life.
Pulmonary Fibrosis in Animals
Lung scarring is not unique to humans. Cats, in particular, develop a spontaneous form of idiopathic pulmonary fibrosis that closely mimics the human version. The scarring pattern includes the same fibroblast-rich foci, honeycombing, and abnormal cell changes seen in human IPF. On an ultrastructural level, the defects in the lining cells of the air sacs in affected cats resemble those seen in a hereditary form of human IPF.24Chest / PubMed Central. Identification of spontaneous feline idiopathic pulmonary fibrosis: morphology and ultrastructural evidence for a type II pneumocyte defect This is more than a veterinary curiosity. Because mice, the standard laboratory model, do not perfectly replicate human IPF, naturally occurring disease in cats could eventually serve as a more faithful model for testing new therapies. For cat owners, it is worth knowing that a middle-aged or older cat with unexplained rapid breathing and exercise intolerance may be experiencing fibrotic lung disease, not just asthma or heart problems.